This conference will bring together all stakeholders from regulators to governments, from national competent authorities to the European Medicines Agency in London and from industry, payers and the ultimate beneficiary of a successfully functioning system the patients who stand to benefit from the fruits of innovative R&D. The objective is to move from a What is happening? to How will we make this what into a functioning reality that achieves the multiple different objectives from all involved stakeholders?
Key Topics: - Mapping the HTA Landscape in Europe
- Risk-sharing Schemes and Conditional Reimbursement
- Methodologies to Generate the Right Data
- Building Benefit Management Plans
Special Discount The 2nd DIA Health Technology Assessment Conference is immediately following the DIA Future Direction for Orphan Drugs in Europe Conference on 3 November. The first half day of the HTA Conference continue the discusson on Oprhan Drugs. Delegates are encouraged to register for both conferences to take advantage of valuable crossover sessions. Benefit from a combined rate and a chance to save up to 600!
Target Audience:
The aim of this one and a half day conference is to bring together professionals working in the following areas:
- Pharmacoepidemiology / Quality of Life / Health Economics / Outcomes Research /Managed Healthcare
- Public Policy / Law
- Regulatory Affairs / Policy / Drug or Device Approval
- Clinical Research and Development
- Research and Development / Strategic Issues
- Government
